

ERRATA CORRIGE

In the article by G. Giraud, G. Bogdanovic, P. Priftakis, M. Remberger, B.M. Svahn, L. Barkholt, O. Ringden, J. Winiarski, P. Ljungman, T. Dalianis. The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. *Haematologica* 2006; 91:401-404, a wrong version of Table 1 has been published. Correct version is now presented below.

doi: 10.3324/haematol.13876

Table 1. Clinical characteristics and donor background of 90 HSCT recipients, evaluated for hemorrhagic cystitis in relation to their conditioning regimen.

	RIC	Myeloablative
Patients	46	44
Sex (Male/Female)	30/16	23/21
Median age (Min-Max)	52 (6-64)	13 (0.7-59)*
Donors		
Related	17	15
Unrelated	29	29
Underlying Diagnosis		
Leukemia	18	36
Lymphoproliferative disorder	7	1
Non-malignant disorder	3	5
Others	2	2
Solid tumor	16	0
Disease stage		
Early disease/late disease	10/20	21/23
GVHD prophylaxis		
CsA+MTX	39	34
Other combinations	7	10
Conditioning		
Flu+flTBI 6Gy +Cy	7	
Flu+TBI 2 Gy	1	
Flu+Bu	17	
Flu+Cy	19	
Flu+treosulfan	2	
flTBI 12Gy+Cy		18
Bu+Cy		24
Cy		2
Anti-thymocyte globulin	39	32
Stem cell source (BM/PBSC/CB)	9/36/1	19/22/3*
CD34 ⁺ dose (10 ⁶ /kg)	7.8 (0.6-28.0)	7.2 (0.1-66.0)

* $p < 0.01$. Early disease; first complete remission, first chronic phase and non-malignant disease/late disease; all others, solid tumors not included. CsA; cyclosporine, MTX; methotrexate, Flu; fludarabine, flTBI; fractionated total-body irradiation, Cy; cyclophosphamide, Bu; busulphan, ATG; BM; bone marrow, PBSC; peripheral blood stem-cells; CB; cord blood.